ALT 🔬 Our picks: 1️⃣ LBA1 – LATIFY: Ceralasertib + durvalumab post-IO NSCLC — B. Besse 2️⃣ LBA2 – i-TIMES: Timing of immunotherapy – first results — S. Peters 3️⃣ LBA3 – NorthStar: Local consolidative RT in EGFRm NSCLC — S. Gandhi 4️⃣ LBA4 – OptiTROP-Lung03: Sac-TMT final OS in EGFRm NSCLC — Y. Yang 5️⃣ LBA5 – One-time low dose CT screening & lung cancer mortality — C. Li 6️⃣ 1O – Setidegrasib in KRAS G12D-mutant NSCLC — L. Paz-Ares 7️⃣ 2O – TOP study: Osimertinib ± chemo in TP53-mutant EGFRm NSCLC — Y. Yang 8️⃣ 3O – PRESERVE-003: Gotistobart vs docetaxel in sqNSCLC — K. He 9️⃣ 4MO – KANDLELIT-001: MK-1084 + pembro in KRAS G12C — A. Sacher 🔟 5MO – ADEPPT: Adagrasib in elderly/poor PS KRASG12C NSCLC — J. Naidoo